Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), an…

Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) ...

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research ---- The Hoffman ALS Clinical Trial Awards ...
News-Medical.Net on MSN

How the gut microbiome links obesity to colorectal cancer

The gut microbiome serves as both a biomarker and therapeutic target in diseases like obesity, metabolic syndrome, and ...
News-Medical.Net on MSN

Kinase inhibitors can accelerate the degradation of target proteins, study reveals

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by ...
The American Journal of Managed Care

KYV-101 Achieves Durable Response in Myasthenia Gravis

KYV-101 demonstrated significant efficacy in reducing MG-ADL and QMG scores in gMG patients, with rapid and sustained effects ...

From inhibition to destruction: Kinase drugs found to trigger protein degradation

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by ...
Johns Hopkins Medicine

Scientists Get Detailed Look at Part of a Cellular ‘Stress’ Warning Protein

In an effort to reveal the inner workings of a protein that serves as a cell’s damage detection system, scientists at Johns ...